Radiation-induced HIF-1α cell survival pathway is inhibited by soy isoflavones in prostate cancer cells

International Journal of Cancer

Volumn 124, Issue 7, 2009, Pages 1675-1684

  Singh Gupta, Vinita ^a   Zhang, Hao ^a   Banerjee, Sanjeev ^a   Kong, Dejuan ^a   Raffoul, Julian J ^a   Sarkar, Fazlul H ^a   Hillman, Gilda G ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b 515 Hudson Webber Cancer Research Center ^*  (United States)

Author keywords

Prostate cancer; Radiation; Signaling pathways; Soy

Indexed keywords

ANDROGEN; COMPLEMENTARY DNA; DAIDZEIN; GENISTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOFLAVONE; STAT3 PROTEIN; STEROID RECEPTOR COACTIVATOR 1; VASCULOTROPIN; APEX1 PROTEIN, HUMAN; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; HIF1A PROTEIN, HUMAN; ISOFLAVONE DERIVATIVE; PROTEIN TYROSINE KINASE; VASCULOTROPIN A;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL NUCLEUS TRANSPLANTATION; CELL SURVIVAL; CONTROLLED STUDY; DNA BINDING; DRUG MECHANISM; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; RADIATION EXPOSURE; RADIATION RESPONSE; TRANSCRIPTION INITIATION; TUMOR GROWTH; VASCULAR ENDOTHELIUM; CHEMISTRY; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; GEL MOBILITY SHIFT ASSAY; METABOLISM; PHOSPHORYLATION; PROSTATE TUMOR; SIGNAL TRANSDUCTION; SOYBEAN; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL LINE, TUMOR; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ISOFLAVONES; MALE; NF-KAPPA B; PHOSPHORYLATION; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; SOYBEANS; SRC-FAMILY KINASES; STAT3 TRANSCRIPTION FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 61449206288     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24015     Document Type: Article

References (49)

1. Khan N, Afaq F, Mukhtar H. Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid Redox Signal 2008;10: 475-510.
2. Sarkar FH, Li Y. Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res 2006;66:3347-50.
3. Raffoul J, Sarkar F, Hillman G. Radiosensitization of prostate cancer by soy isoflavones. Cancer Drug Targets 2007;7:759-65.
4. Hillman GG, Forman JD, Kucuk O, Yudelev M, Maughan RL, Rubio J, Layer A, Tekyi-Mensah S, Abrams J, Sarkar FH. Genistein potentiates the radiation effect on prostate carcinoma cells. Clin Cancer Res 2001;7:382-90.
5. Hillman GG, Wang Y, Kucuk O, Che M, Doerge DR, Yudelev M, Joiner MC, Marples B, Forman JD, Sarkar FH. Genistein potentiates inhibition of tumor growth by radiation in a prostate cancer orthotopic model. Mol Cancer Ther 2004;3:1271-9.
6. Raffoul JJ, Wang Y, Kucuk O, Forman JD, Sarkar FH, Hillman GG. Genistein inhibits radiation-induced activation of NF-kB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest. BMC Cancer 2006;6:107.
7. Wang Y, Raffoul JJ, Che M, Doerge DR, Joiner MC, Kucuk O, Sarkar FH, Hillman GG. Prostate cancer treatment is enhanced by genistein in vitro and in vivo in a syngeneic orthotopic tumor model. Radiat Res 2006;166:73-80.
8. Raffoul JJ, Banerjee S, Che M, Knoll ZE, Doerge DR, Abrams J, Kucuk O, Sarkar FH, Hillman GG. Soy isoflavones enhance radiotherapy in a metastatic prostate cancer model. Int J Cancer 2007;120: 2491-8.
9. Raffoul JJ, Banerjee S, Singh-Gupta V, Knoll ZE, Fite A, Zhang H, Abrams J, Sarkar FH, Hillman GG. Down-regulation of apurinic/apyrimidinic endonuclease 1/redox factor-1 expression by soy isoflavones enhances prostate cancer radiotherapy in vitro and in vivo. Cancer Res 2007;67:2141-9.
10. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
11. Syed DN, Khan N, Afaq F, Mukhtar H. Chemoprevention of prostate cancer through dietary agents: progress and promise. Cancer Epidemiol Biomarkers Prev 2007;16:2193-203.
12. Morgan PB, Hanlon AL, Horwitz EM, Buyyounouski MK, Uzzo RG, Pollack A. Radiation dose and late failures in prostate cancer. Int J Radiat Oncol Biol Phys 2007;67:1074-81.
13. Holzbeierlein J, McIntosh J, Thrasher J. The role of soy phytoestrogens in prostate cancer. Curr Opin Urol 2005;15:17-22.
14. Sarkar FH, Li Y. The role of isoflavones in cancer chemoprevention. Front Biosci 2004;9:2714-24.
15. Lin A, Karin M. NF-kappaB in cancer: a marked target. Semin Cancer Biol 2003;13:107-14.
16. Sweeney C, Li L, Shanmugam R, Bhat-Nakshatri P, Jayaprakasan V, Baldridge LA, Gardner T, Smith M, Nakshatri H, Cheng L. Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adeno-carcinoma ofthe prostate. Clin Cancer Res 2004;10:5501-7.
17. Shukla S, MacLennan GT, Fu P, Patel J, Marengo SR, Resnick MI, Gupta S. Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia 2004;6:390-400.
18. Robson CN, Hickson ID. Isolation of cDNA clones encoding a human apurinic/apyrimidinic endonuclease that corrects DNA repair and mutagenesis defects in E. coli xth (exonuclease III) mutants. Nucleic Acids Res 1991;19:5519-23.
19. Evans A, Limp-Foster M, Kelley M. Going APE over Ref-1. Mutat Res 2000;461:83-108.
20. Kelley MR, Cheng L, Foster R, Tritt R, Jiang J, Broshears J, Koch M. Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/ref-1 in prostate cancer. Clin Cancer Res 2001;7:824-30.
21. Jiang BH, Semenza GL, Bauer C, Marti HH. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of 02 tension. Am J Physiol 1996;271:C1172-C1180.
22. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA 1993;90:4304-8.
23. Huang L, Arany Z, Livingston D, Bunn H. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its a-subunit. J Biol Chem 1996;271:32253-59.
24. Subarsky P, Hill RP. The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis 2003;20:237-50.
25. Wouters A, Pauwels B, Lardon F, Vermorken JB. Review: implications of in vitro research on the effect of radiotherapy and chemotherapy under hypoxic conditions. Oncologist 2007;12:690-712.
26. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004;4:470-80.
27. Chang YM, Kung HJ, Evans CP. Nonreceptor tyrosine kinases in prostate cancer. Neoplasia 2007;9:90-100.
28. FizaziK. The role of Srcinprostate cancer. AnnOncol2007;18: 1765-73.
29. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004;4:97-105.
30. Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S, Gritsko T, Turkson J, Kay H, Semenza GL, Cheng JQ, Jove R. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 2005;24:5552-60.
31. Bektic J, Guggenberger R, Eder IE, Pelzer AE, Berger AP, Bartsch G, Klocker H. Molecular effects of the isoflavonoid genistein in prostate cancer. Clin Prostate Cancer 2005;4:124-9.
32. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994;54:2577-81.
33. Bhuiyan MM, Li Y, Banerjee S, Ahmed F, Wang Z, Ali S, Sarkar FH. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res 2006;66:10064-72.
34. Balan V, Leicht DT, Zhu J, Balan K, Kaplun A, Singh-Gupta V, Qin J, Ruan H, Comb MJ, Tzivion G. Identification of novel in vivo Raf-1 phosphorylation sites mediating positive feedback Raf-1 regulation by extracellular signal-regulated kinase. Mol Biol Cell 2006;17:1141-53.
35. Chaturvedi MM, Mukhopadhyay A, Aggarwal BB. Assay for redoxsensitive transcription factor. Methods Enzymol 2000;319:585-602.
36. Kong D, Li Y, Wang Z, Banerjee S, Sarkar FH. Inhibition of angiogenesis and invasion by 3,3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 2007;67:3310-19.
37. Vengellur A, LaPres JJ. The role of hypoxia inducible factor 1alpha in cobalt chloride induced cell death in mouse embryonic fibroblasts. Toxicol Sci 2004;82:638-46.
38. Lo FH, Mak NK, Leung KN. Studies on the anti-tumor activities of the soy isoflavone daidzein on murine neuroblastoma cells. Biomed Pharmacother 2007;61:591-5.
39. Choi EJ, Kim GH. Daidzein causes cell cycle arrest at the G1 and G2/ M phases in human breast cancer MCF-7 and MDA-MB-453 cells. Phytomedicine 2008;15:683-90.
40. Wang D, Luo M, Kelley MR. Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol Cancer Ther 2004;3:679-86.
41. Robertson KA, Bullock HA, Xu Y, Tritt R, Zimmerman E, Ulbright TM, Foster RS, Einhorn LH, Kelley MR. Altered expression of Ape1/ ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation. Cancer Res 2001;61:2220-5.
42. Fishel ML, Kelley MR. The DNA base excision repair protein Apel/ Ref-1 as a therapeutic and chemopreventive target. Mol Aspects Med 2007;28:375-95.
43. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003;9:677-84.
44. Harada H, Kizaka-Kondoh S, Li G, Itasaka S, Shibuya K, Inoue M, Hiraoka M. Significance of HIF-l-active cells in angiogenesis and radioresistance. Oncogene 2007;26:7508-16.
45. Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS, Gallick GE. HIF-lalpha, STAT3, CBP/p300 and Ref- 1/APE are components of a transcriptional complex that regulates. Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 2005;24:3110-20.
46. Chao C, Goluszko E, Lee YT, Kolokoltsov AA, Davey RA, Uchida T, Townsend CM, Jr, Hellmich MR. Constitutively active CCK2 receptor splice variant increases Src-dependent HIF-1 alpha expression and tumor growth. Oncogene 2007;26:1013-19.
47. Zhang X, Kon T, Wang H, Li F, Huang Q, Rabbani ZN, Kirkpatrick JP, Vujaskovic Z, Dewhirst MW, Li CY. Enhancement of hypoxia- induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1alpha. Cancer Res 2004;64:8139-42.
48. Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004;5:429-41.
49. Kunz M, Ibrahim SM. Molecular responses to hypoxia in tumor cells. Mol Cancer 2003;2:23.